



THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Gregory Prince

SERIAL NO: 09/848,377

Group Art Unit: 1648

FILED: May 3, 2001

Examiner: Hill, M. G.

FOR: Combination Therapy of Respiratory Diseases Using Antibodies...

DOCKET NO: 469201-540

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449, which may be material to the patentability of the above-identified application. Applicant(s) make no admission that the cited references are prior art or that these references are in fact material to the patentability of the above-entitled application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

 §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

 X §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

03/21/2006 MBIZUNES 00000010 09848372

01 FC:1806

180.00 OP

is accompanied by either: (check one)

☐ The statement as specified in 37 CFR §1.97(e) set out below; OR

☒ The fee of \$ 180.00 under 37 CFR §1.17(p).

☐ §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

(1) a Final Action or under 37 CFR §1.113; OR

(2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

(1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND

(2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,

(3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

☐ §1.97(e) The undersigned Attorney hereby states that:

☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;
or

☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.


The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Serial No: 09/848,377
Filed: May 3, 2001

FIRST CLASS CERTIFICATE


I hereby certify that this
correspondence is being deposited
today with the U.S. Postal Service as
First Class Mail in an envelope
addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

 3/14/06

Alan J. Grant, Esq. Date

Respectfully submitted,



Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
5 Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT

Atty. Docket:
469201-540Serial No.:
09/848,377

Applicant: Gregory Prince

Filing Date: May 3, 2001

Group: 1648

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1						
	B1						
	C1						
	D1						
	E1						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	F1						<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	G1						<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	H1	Bulow et al., Prednisolone treatment of Respiratory Syncytial Virus Infection: a randomized controlled trial of 147 infants, <i>Pediatrics</i> , 104 (6 December 1999), p e77)
	I1	
	J1	
	K1	
	L1	
	M1	
	N1	
	O1	
	P1	
	Q1	

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.